Colomycin
ApprovedSmall molecule
Colomycin is one of 67 small molecule programs targeting Bronchiectasis. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
386 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Colomycin
UUniversity of Edinburgh
Approved
Onglyza
AstraZenecaPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Actimmune
HHorizon Therapeutics Ireland DAC
Preclinical
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Aztreonam Lysine
GileadPreclinical
Amitiza
SSucampo Pharma Americas, LLC
Preclinical
Capromorelin
UUniversity of Aarhus
Preclinical
Advil
KKenvue Brands
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Colomycin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Edinburgh